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Summary 
Transcribing the theoretical aspect of continuous renal replacement therapy (CRRT) to the 
bedside and delivering a given dose can be difficult. Our aim was to design an excel calculator 
which would personalise patient’s treatment, deliver an effective, evidence based dose of RRT 
without large variations in practice and prolong filter life. Our calculator prescribes a 
haemodialfiltration dose of 25ml.kg-1.hr-1 whilst limiting the filtration fraction to 15%.  We 
compared the data from a historical group to a calculator group. The median delivered dose 
reduced from 41.0 ml.kg-1.hr-1 to 26.8 ml.kg-1.hr-1 with reduced variability that was significantly 
closer to the aim of 25 ml.kg-1.hr-1 (p<0.0001). The median treatment time increased from 8.5hr 
to 22.2hr (p=0.00001). Our calculator significantly reduces variation in prescriptions of CVVHDF 
and provides an evidence-based dose. It is easy to use and provides personal care for patients 
whilst optimizing CVVHDF delivery and treatment times. 
 
Introduction  
The practice of continuous renal replacement therapy (CRRT) has received much scrutiny 
recently. Issues such as the timing of initiation [1], timing of termination [1,2], type of therapy 
[3] and dose of therapy [3,4,5], have received considerable attention. The need to write a daily 
prescription for patients who require CRRT is considered a marker of good clinical practice [6] 
and there is now good evidence for an optimal dose of renal replacement therapy. [5] In reality, 
transcribing the theoretical aspects of CRRT to the bedside and delivering a given ‘dose’ can be 
difficult. There is a higher turnover of junior medical staff and the complexity of the machinery 
increases the chances of error. 
 
Our unit is a 24 bedded critical care providing Level 2 and 3 care. In 2011 we had admitted 1326 
patients.  RRT was received by 157 individuals, resulting in 768 RRT days. We deliver continuous 
veno-venous haemodiafiltration (CVVHDF) using the Prismaflex  (Gambro Ltd) machine. An audit 
revealed a huge variation in treatment regimes and that many of our CVVHDF circuits 
prematurely failed, usually well before the maximum 72 hours recommended by the 
manufacturer. Changes in prescription, in particular alterations in blood flow rates are a 
recognized cause. [7,8] This was costly and represented a failure to deliver adequate renal 
support due to the prolonged filter downtimes, a phenomenon that has been also been 
recognized [9]. A number of problems were identified. Our protocol was to prescribe high blood 
flow rates on initiation, up to 300ml.min-1. If the circuit access pressure exceeded -100mmHg or 
the return pressure exceeded +100mmHg then the blood flow rate was reduced so as not to 
exceed these limits. We had observed that early circuit failure occurred when blood flow 
through the indwelling vascular catheter was suboptimal due to kinking, hypovolaemia or 
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inadequate anticoagulation. Our protocol directed the nursing staff to achieve as high a blood 
flow rate as possible and compounded this problem.  
 
The medical staff wished to see evidence based dosing of RRT.  The literature now points to 
optimal effluent flow rates of 25ml.kg-1.hr-1 although higher rates were the norm prior to the 
publication of the RENAL study. [4,5] However in our practice, this was not translating into 
consistent prescribing of ultrafiltrate and dialysate flow rates or an appropriate blood flow rate 
to support these goals. Our aim was to design an excel calculator which would personalise 
patient’s treatment, deliver an effective, evidence based dose of RRT without large variations in 
practice and prolong filter life. 
 
Method 
The Yorkshire and The Humber Leeds East ethics committee granted ethical approval after 
proportionate review (ref 14/YH/1004). Patient consent was not required.  
 
A calculator had been designed in 2005 by Ricci et al as a way of retrospectively auditing the 
delivered dose of RRT within their unit [10]. This used calculations that had been validated in a 
previous study by [11]. We developed this further. The first premise was that the ‘dose’ of 
CVVHDF should be 25ml.kg-1.hr-1. The second was that ultrafiltrate, dialysate and blood flow 
rates were appropriately matched, and that the filtration fraction did not exceed 15%. The third 
was a blood flow checker. It is unnecessary to run blood flows as high as 300ml.min-1 for most 
patients. However, if blood flow rates are set too low, then clotting within the circuit is likely to 
occur. We estimated that a blood flow rate of 160 ml.min-1 should be adequate for most 
patients. The fluid solutions were standard lactate based solutions. If the patient was 
hyperkalaemic, a potassium free solution was used for the replacement and dialysate. We 
converted to such a bag when the serum potassium was >5.5mmol.L-1. The clinician precribed 
the hourly fluid loss. 
 
We recruited all patients that had CVVHDF who were aged 18 and over. We excluded patients 
that required CVVHDF for less than 24hours and who required CVVHDF for fluid removal only.  
The historical controls were all patients receiving CVVHDF between January 2012 and June 2012 
(six months). The data was collected from the inbuilt Prismaflex (Gambro) data card. Additional 
patient details were then taken from the hospital computer system (when available). 
Epidemiological data was collected for the patients: age, sex, patient weights, APACHE2 and 
ICNARC scores. 
 
In the prospective calculator group, the research team was informed when the clinical team 
decided to start CVVHDF. The clinical team used the calculator to prescribe the CVVDHF. Data 
regarding the therapy session was collected from a clean electronic data card within the 
Prismaflex machine as well as a manual recording form completed by the nursing staff attending 
the patient.  
 
The primary hypothesis was that the calculator would provide an average hourly CVVHDF dose 
of 25ml.kg-1.hr-1 with a reduction in the variation of practice. The secondary endpoints were an 
increase in the treatment time of each filter set and a change in the total volume of effluent 
fluid used. The prospective study would also examine the type and number of changes made to 
the prescribed regime.  
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The power was determined using the Monte Carlo method of calculating probability 
distribution. Our previous audit data had 71 filter episodes from 45 patients with a wide 
variability in data. Assuming the calculator delivered 25-30ml.kg-1.hr-1, then a sample of just 5 
filter episodes would be adequate to show a reduction in variability. However a sample size of 
30 filter episodes would ensure that we accurately represented the intervention population. 
Normally distributed data is presented as mean (standard deviation), non-normal data as 
median (interquartile range). The difference in variation of the effluent flow rates is measured 
by the Monte Carlo method for non-normal data. Differences in treatment times and total 
effluent are calculated with the Mann-Whitney U test.  
 
Results 
The historical data was collected from the electronic CVVHDF machine log between January 
2012 and June 2012. The individual patient details entered into the machine at that time were 
not sufficient to provide an adequate summary of the historical group’s demographic data. The 
calculator group’s data was complete and was collected between December 2013 and May 
2014, after the calculator was introduced. The demographic data is displayed in Table 1.  
 
 
The patients in the calculator group had a lower median flow rate of 26.8ml.kg-1.hr-1 (IQR 25.2-
29.0) compared to the historical group that had a median flow rate of 41.0ml.kg-1.hr-1 (IQR 29.0-
89.0) (Table 2). Since the historical effluent rates were significantly non-normal, we performed a 
Monte Carlo test using bootstrapping from both empirical distributions. The p-value <0.0001 
shows that the prospective effluent rates were significantly closer to the optimum of 25ml.kg-
1.hr-1 compared with the historical effluent rates. The effluent flow rates are compared in the 
boxplots in Figure 1.  
 
Figure 1. Box plots show the median, interquartile range and outlying flow rates before and 
after the introduction of the calculator. The flow rates after the calculator was introduced were 
significantly closer to 25ml.kg-1.hr-1 than those before the calculator with less variability 
(p<0.0001). 
 
The treatment times were significantly longer in the calculator group. The median (IQR) was 
22.2hr (16.5-44.6) as compared to 8.5hr (2.8-23.0). Mann-Whitney U test for non-parametric 
data showed p<0.00001 (Figure 2). Before the calculator was introduced there were nine (12%) 
treatments that lasted less than one hour compared to zero after the introduction of the 
calculator. As a result the total effluent increased from 29.9L (8.6-111.0) to 60.0L (32.1-119.4), 
p=0.003 (Figure 3). See Table 2. 
 
Figure 2. Box plots show the median, interquartile range and outlying treatment times before 
and after the introduction of the calculator. The treatment times after the calculator was 
introduced were significantly longer than those before the calculator (p<0.00001). 
 
Figure 3. Box plots show the median, interquartile range and outlying total effluent volumes 
before and after the introduction of the calculator. The total effluent volumes after the 
calculator was introduced were significantly larger than those before the calculator (p<0.0003). 
 
In the calculator group it was recorded if changes had been made to the settings on the CVVHDF 
machine (Table 3). The most commonly changed parameter was the hourly fluid removal, which 
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was changed on 17 (60%) treatments. During 11 (39%) of treatments the blood flow was 
changed, eight (28%) changed the pre-bloodpump flow, nine (32%) made a change to the 
ultrafiltrate flowrate and seven (25%) changed the dialysate flowrate.  
 
The median number of changes varied between one and two for each variable. The blood flow 
rate was changed the most number of times; median 2 (2-6), and the pre-bloodpump flow rate 
was changed the least number of times; median 1(1-2).   
 
We used linear models to test whether any of the variables (runtime, weight, blood flowrate, 
pre-bloodpump flowrate, replacement fluid flowrate, dialysate fluid flowrate and fluid removal 
rate) were significantly related to the effluent rate in the prospective cohort. Starting from the 
saturated model, we used stepwise backward selection to remove any non-significant variables. 
The only significant predictor of the effluent rate in the prospective cohort was weight, each one 
kilogram increase in weight was associated with a decrease in effluent rate of 0.053ml.kg-1.hr-1  
(p-value 0.04, 95% confidence interval 0.0023 to 0.10). A residual analysis showed that the 
model appeared to fit the data well, although there is likely to be low-predictive power from it, 
the adjusted Rˆ2 of the fit being 0.12.  
 
Discussion 
The study has proven its primary endpoint. The calculator achieved a median effluent flow rate 
of 26.8ml.kg-1.hr-1 (25.2-29.0ml.kg-1.hr-1). This is an absolute reduction of 14.2ml.kg-1.hr-1 from 
41.0ml.kg-1.hr-1 and the reduction in the variance was highly significant (p<0.0001). This proves 
that we have achieved our aim to introduce a spreadsheet calculator that is easy to use and 
successfully recreates flow rates that have been shown to deliver adequate clearance. [5] The 
reduction in variance of the prescriptions used indicates a more consistent approach to 
delivering CVVHDF as guided by previous evidence and has proved a valuable educational tool 
on our critical care. Removing human factors is important as critical care units in the UK are 
increasingly staffed by junior doctors without a background in intensive care, who rotate 
frequently. 
 
We attribute the significant increase in the treatment times from 8.5hr to 22.2hr (p=0.0003) to 
ensuring that the filtration fraction remained below 15%. Limiting fluid replacement according 
to weight and haematocrit prevents haemoconcentration within the filter and prolongs filter 
life. Further requirements for clearance are met with dialysate. Longer treatment times are 
more efficient at delivering CVVHDF as there are fewer periods spent without CVVHDF. The 
benefit to the patient increases as they receive greater clearance and lose less blood, whilst 
there is also a reduced cost of filter sets. Reducing the blood flow rate ensured that there were 
no filters that lasted less than one hour and represents a major improvement in practice. It is 
noted that the median treatment time is 22.2 hours which is still below the maximum time per 
filter of 72 hours. However treatments are stopped for other reasons such as being no longer 
required, or because the patient is transferred off the unit. The total effluent per treatment 
increased despite the marked reduction in the effluent flow rate. This reflects the increased 
treatment time and likely reflects an increase in the plasma clearance per 24 hours.  
 
Changes to the CVVHDF prescription occurred despite the use of the calculator. The most 
commonly changed (60% of treatments) was the hourly fluid removal rate. This was expected as 
this will change according to clinical need. Changes to the replacement and dialysate rates 
would change the clearance. The fact that the median effluent rate is 26.8 ml.kg-1.hr-1, not the 
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intended 25 ml.kg-1.hr-1 indicates that these rates were increased, most likely guided by the 
patient’s biochemistry. Thirty-nine percent of the treatments saw an adjustment of the blood 
flow rate. This is more concerning as it directly effects the filtration fraction. It may explain why 
changes were made to the pre-bloodpump dilution (28%) that may be required if the blood flow 
rate has been reduced too much. It is reassuring that whilst the median treatment time 
increased to 22.2hr the median number of changes for any of the flow rates was two.   
 
Pisitkun [10] initially designed and validated a calculator with the purpose of determining the 
clearance achieved by renal replacement therapy across a number of modalities. Having been 
validated, the calculations were then used to test a number of different modalities of RRT 
including CVVHDF [11]. They used it to assess the adequacy of the clearance and filtration 
fraction for the flowrates that they had decided to use. They did not start with a desired dose 
and use it to predict the flow rates necessary to achieve it. Banks (12), described a similar 
calculator to ours, which he used on his unit. The main difference between our calculator and 
his was that he kept the dialysate and ultrafiltrate rate the same thereby producing a quadratic 
equation which gave an effluent flow rate to produce a desired clearance. Blood flow rates were 
variable and no attention was paid to filtration fraction. We took a different approach based on 
the audit of our previous practice. We fixed our blood flow rate and filtration fraction so as to 
determine replacement rates. Haemoconcentration is less likely to occur and so circuit longevity 
should be increased when the filtration fraction remains below 15%. Dialysate was added to 
provide a total effluent flow rate of 25ml.kg-1.hr-1. 
 
There are problems with this study. It was not randomised or blinded. The calculator had been 
introduced into clinical practice and audit had been used to improve its usability. It was seen to 
bring about improvement and so it would have been unethical to withdraw it from practice in 
order to randomise. The educational elements were also changing practice. It was not possible 
to blind practice because of the nature of the intervention. Using historical controls introduces 
bias and it possible that other improvements in practice occurred during that time. It is also 
possible that the CVVHDF was optimised in other ways because of the study conditions; line 
positions could have been optimised, treatments not “electively” stopped and more attention 
given to anticoagulation.  
 
The study was a pragmatic one and alterations to the prescription were allowed. This requires 
further study. Improving our understanding of why changes are made will provide users with 
clearer instructions on how to change the prescription. Future additions to the calculator could 
include heparin or citrate infusions. If future randomised controlled trials mandate a change in 
CVVHDF flowrates, then the calculator equations can be changed and the change introduced 
immediately without further staff training. This is an additional improvement to change 
management.  
 
We have proven that our calculator significantly reduces variation in prescriptions of CVVHDF 
and provides an evidence-based dose. It is easy to use and provides personal care for patients 
whilst optimizing CVVHDF delivery and treatment times.  
 
No external funding and no competing interests. 
 
Appendix 1.The Calculations 
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The initial premise is that the filtration fraction (F.F) should be not more than 20% of the circuit 
plasma flow. For all patients the calculation uses a filtration fraction of 15% of total plasma flow.  
 
Equation 1.  Plasma flow (Q.pl) =Total blood flow x (1-Hct). 
 
We deliver CVVHDF using the Prismaflex (Gambro) machine which delivers a filterflux of: 
 
Equation 2. Filterflux =Postfilter fluid replacement (Q.post)+ Fluid removal rate (Q.r) 
  
Pre-filter fluids are pumped into the circuit to prolong filter life, (“pre-dilution”), and this fluid 
becomes part of the plasma flow. 
 
Equation 3. Total plasma flow = Plasma flow (Q.pl) + Predilution (Q.pre)  
 
Combining these equations:  
 
Equation 4. Filtration fraction= Q.post + (Q.r/Q.pl) +Q.pre 
 
Or, reorganising this: 
 
Equation 5.  Qpl = (Q.post +Q.r)/FF – Q.pre 
 
To convert this to the minimum blood flow (BFmin) setting then multiply Q.pl by 1/1-Hct. 
 
Equation 6.  BFmin = [(Q.post+Q.r)/FF-Q.pre]x(1/1-Hct) 
 
The second premise in delivering the dose is that the fluid replacement (Qrep), the dialysis fluid 
flow rate (Qdial) and the removal rate (Qr) should also deliver an adequate dose based on the 
standard dialysis formula of Kt/Vd = 1.4. If it is assumed that the percentage of patient weight 
that is body water is 60% then this also equates to a total effluent of 25ml.kg-1.hr-1 when 
CVVHDF runs continuously. 
 
Equation 7. K = Qrep + Qdial 
 
Where Qrep = replacement rate and Qdial = dialysate rate.  
 
Equation 8.  Kt/Vd = (Qrep + Qdial + Qr) x time / Mass x 0.6 x 1000 
 
Where mass=Kg, 0.6 represents 60% water volume and multiplying by 1000 converts the volume 
to millilitres. The Prismaflex machine automatically delivers the hourly removal in addition to 
the replacement fluid. Therefore: 
 
Equation 9.  Total effluent (Qrep + Qdial + Qr) = (1.4 x Mass x 0.6 x 1000)/t 
 
The filtration fraction is calculated from the amount of fluid removed from the plasma, in this 
case Qrep and Qr. The dialysate does not remove a volume of fluid from the plasma, but we 
assume complete clearance of solutes across the membrane. (This holds true for urea but may 
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not be true for other toxins or drugs). If the filtration fraction remains constant, the replacement 
is therefore governed by the blood flow. Rearranging Equation 6: 
 
Equation 10.  Qrep = ((((BFmin x (1-Hct)) + Qpre) x 0.15) - Qr 
 
The dialysate makes up the remainder of the total effluent and does not affect the filtration 
fraction. 
 
Equation 11.  Qdial = Total effluent - Qrep - Qrem 
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Table 1. Demographic data after introduction of the calculator. Several patients had multiple 
treatments.  
Variable Post Calculator Group 
Records; n 28 
Patients; n  15 
Age; year*  62.2 ± 13.8 
Weight; kg 98.2 ± 38.8 
Apache 2† 22.9 ± 5.5 
LOS; day‡ 5.0 (3.0-20.7) 
Outcome Alive; n (%) 11 (73%) 
Outcome Death; n (%) 4 (27%) 
*Mean±SD, †n ± SD, ‡Median (IQR). 
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Table 2. Flow rate and runtimes collected from the electronic data cards. All data are median 
(IQR). 
Variable Historical Post Calculator P value 
Flow rate; ml.kg-1.hr-1 41.0 (29.0-89.0) 26.8 (25.2-29.0) <0.0001 
Total effluent; L 29.9 (8.6-111.0) 60.0 (32.1-119.4) <0.00001 





Table 3. The number of treatments in the prospective group in which a treatment was changed 
after the calculator, and how many changes occurred. Data presented as median (IQR). 
 
Variable Treatments changed,  
n (%) 
Number of changes per 
treatment, n  
Blood flowrate 11 (39) 2 (2-6) 
Pre-Bloodpump flowrate 8 (28) 1 (1-2) 
Replacement fluid flowrate 9 (32) 1 (1-3) 
Dialysate fluid flowrate 7 (25) 2 (1-3.5) 
Fluid removal rate 17 (60) 2 (1-3) 
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